SE450088B - Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer - Google Patents

Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer

Info

Publication number
SE450088B
SE450088B SE8101582A SE8101582A SE450088B SE 450088 B SE450088 B SE 450088B SE 8101582 A SE8101582 A SE 8101582A SE 8101582 A SE8101582 A SE 8101582A SE 450088 B SE450088 B SE 450088B
Authority
SE
Sweden
Prior art keywords
mice
granulosum
preparations
tumors
treatment
Prior art date
Application number
SE8101582A
Other languages
English (en)
Swedish (sv)
Other versions
SE8101582L (sv
Inventor
G Pulverer
Original Assignee
Madaus & Co Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus & Co Dr filed Critical Madaus & Co Dr
Publication of SE8101582L publication Critical patent/SE8101582L/
Publication of SE450088B publication Critical patent/SE450088B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE8101582A 1980-03-25 1981-03-12 Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer SE450088B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3011461A DE3011461C2 (de) 1980-03-25 1980-03-25 Verwendung von Propionibakterien

Publications (2)

Publication Number Publication Date
SE8101582L SE8101582L (sv) 1982-09-13
SE450088B true SE450088B (sv) 1987-06-09

Family

ID=6098254

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8101582A SE450088B (sv) 1980-03-25 1981-03-12 Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer

Country Status (13)

Country Link
US (1) US4647456A (enExample)
JP (1) JPS57165319A (enExample)
AT (1) AT371714B (enExample)
AU (1) AU548596B2 (enExample)
BE (1) BE888770A (enExample)
CA (1) CA1197798A (enExample)
CH (1) CH661868A5 (enExample)
DE (1) DE3011461C2 (enExample)
FR (1) FR2505186A1 (enExample)
GB (1) GB2098478B (enExample)
NL (1) NL189947C (enExample)
NO (1) NO162079C (enExample)
SE (1) SE450088B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678773A (en) * 1983-08-26 1987-07-07 Chugai Seiyaku Kabushiki Kaisha Antitumor agent
DE3817762A1 (de) * 1988-05-26 1989-11-30 Sanum Kehlbeck Gmbh & Co Kg Immunstimulierendes mittel aus propionibakterien sowie verfahren zur herstellung desselben
IL101410A0 (en) * 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
DE19630230A1 (de) * 1996-07-26 1998-01-29 Bayer Ag Herstellung immunstimulierender Mittel auf Basis von Propionibakterien
FR2764802A1 (fr) * 1996-12-24 1998-12-24 Standa Lab Sa Composition adsorbable renfermant des bacteries propioniques susceptible de degager du monoxyde d'azote dans le tube digestif humain ou animal
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
US7709537B1 (en) * 1999-10-19 2010-05-04 Meiji Dairiese Corporation Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials
JP4772245B2 (ja) * 1999-12-13 2011-09-14 バイオニケ ライフ サイエンシーズ インコーポレイテッド 治療上有用な合成オリゴヌクレオチド
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
GB2623078B (en) * 2022-10-03 2025-04-16 Univ Brunel Prevention and/or treatment of wound infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2269961B1 (enExample) * 1974-05-06 1978-03-24 Anvar
FR2269962B1 (enExample) * 1974-05-06 1978-02-03 Anvar
JPS5215894A (en) * 1975-07-29 1977-02-05 Yuichi Yamamura Process for preparing a substance possessing biological actions
JPS5946206B2 (ja) * 1975-10-08 1984-11-10 （株） 目黒研究所 免疫学的活性を有する非病原性好気性コリネバクテリウム培養物の製造法
JPS52108091A (en) * 1976-03-03 1977-09-10 Kowa Co Production of antiitumor substance
JPS5411233A (en) * 1977-06-28 1979-01-27 Asahi Chem Ind Co Ltd Anitidote
JPS5513204A (en) * 1978-06-28 1980-01-30 Mitsui Toatsu Chem Inc Active compound having delayed allergic activity and anticarcinogenic activity, and its preparation
JPS55114290A (en) * 1979-02-27 1980-09-03 Mitsui Toatsu Chem Inc Substance with antitumorigenic activity, its production and medical preparation

Also Published As

Publication number Publication date
BE888770A (fr) 1981-11-12
GB2098478A (en) 1982-11-24
ATA118981A (de) 1982-10-15
US4647456A (en) 1987-03-03
GB2098478B (en) 1985-02-20
AU7024281A (en) 1982-11-11
CH661868A5 (de) 1987-08-31
AU548596B2 (en) 1985-12-19
FR2505186B1 (enExample) 1984-10-12
NO162079B (no) 1989-07-24
NL8101452A (nl) 1982-10-18
NO162079C (no) 1989-11-01
NL189947C (nl) 1993-09-16
DE3011461A1 (de) 1981-10-01
CA1197798A (en) 1985-12-10
JPS57165319A (en) 1982-10-12
JPH0355448B2 (enExample) 1991-08-23
NO810815L (no) 1982-09-13
AT371714B (de) 1983-07-25
NL189947B (nl) 1993-04-16
DE3011461C2 (de) 1986-10-30
FR2505186A1 (fr) 1982-11-12
SE8101582L (sv) 1982-09-13

Similar Documents

Publication Publication Date Title
Johanson et al. The role of bacterial antagonism in pneumococcal colonization of the human pharynx
Bulmer et al. Phagocytosis of Cryptococcus neoformans by alveolar macrophages
Sidransky et al. The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis
Baumgartner et al. Experimentally induced infection by oral anaerobic microorganisms in a mouse model
Baumgartner et al. The incidence of bacteremias related to endodontic procedures I. Nonsurgical endodontics
Gordon et al. Studies on susceptibility to infection following ionizing radiation: IV. The pathogenesis of the endogenous bacteremias in mice
Belsheim et al. Tetracyclines and host defense mechanisms: interference with leukocyte chemotaxis
Davies et al. Human protothecosis: supplementary studies
SE450088B (sv) Anvendning av vissa propionibakterier for framstellning av cellveggsberedningar eller helcellsberedningar for behandling av tumorer
Bluhm et al. Antibiotic prophylaxis in pacemaker surgery: a prospective double blind trial with systemic administration of antibiotic versus placebo at implantation of cardiac pacemakers
Alderman et al. Experimental pyelonephritis. X. Direct injection of E. coli protoplasts into the medulla of the rabbit kidney
Gledhill The effect of bacterial endotoxin on resistance of mice to ectromelia
Balner et al. Reduction of X-ray lethality in mice by agents affecting the reticuloendothelial system
Warring Jr et al. Nonculturable acid-fast forms in the sputum of patients with tuberculosis and chronic pulmonary disease
Freund Hemorrhages in tuberculous guinea pigs at the site of injection of irritants following intravascular injections of injurious substances (Shwartzman phenomenon)
Fitzgeorge et al. The chemical basis of the virulence of Brucella abortus. VII. The production in vitro of organisms with an enhanced capacity to survive intracellularly in bovine phagocytes
Wolinsky et al. Infrequent appearance of drug resistant strains of tubercle bacilli in experimental animals treated with streptomycin and p-amino-salicylic acid
HARTLEY Jr et al. Cervicofacial actinomycosis
Lu et al. Effect of Acanthopanax giraldii Harms Var. Hispidus Hoo polysaccharides on the human gastric cancer cell line SGC-7901 and its possible mechanism
Campbell et al. An apparent growth stimulant for Candida albicans released from tetracycline-treated bacterial flora
Perkins et al. Susceptibility to infection as a function of postirradiation time following oral challenge
Patton et al. Histoplasmosis in purebred mice: influence of genetic susceptibility and immune depression on treatment
Okuda et al. Intraleukocytic bactericidal activity in patients receiving corticosteroid and radiation therapy, and in patients with diabetes mellitus
Klemparskaya et al. Problems of infection, immunity and allergy in acute radiation sickness
Ransmeier The effect of aureomycin against Bacterium tularense

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8101582-8

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8101582-8

Format of ref document f/p: F